文献速递消化系统肿瘤

手术治疗的放疗野内发生的食管癌:对围手术期和长期结局的影响

Surgically treated oesophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes.
PubMed 文献 · Eur J Cancer · 2017-02-23

该研究基于30个欧洲中心2000至2010年数据,比较放疗野内发生的食管癌(ECRF)与原发性食管癌(PEC)的手术结局,以及放疗诱发(RIEC)与非放疗诱发(NRIEC)亚组。ECRF组新辅助放化疗使用更少、切缘阳性率更高、住院死亡率更高,匹配后5年总生存和无事件生存显著降低;RIEC与NRIEC组结局无显著差异。

要点

  • ECRF组新辅助放化疗使用率0% vs PEC组29.5%(P<0.001)。
  • ECRF组R1/2切缘21.3% vs PEC组10.9%(P<0.001),住院死亡率14.0% vs 7.1%(P=0.003)。
  • 匹配后ECRF组5年总生存28.8% vs PEC组50.5%(HR=1.53),无事件生存32.2% vs 42.5%(HR=1.56)。

核心结论

  • ECRF与较差的长期生存相关,原因在于新辅助放化疗使用减少和手术切缘受累增加。
  • 结局似乎更多取决于既往放疗相关的限制,而非放疗诱发的癌变过程。

研究设计与样本

  • 数据来自30个欧洲中心2000至2010年,纳入手术治疗的食管癌患者。
  • 采用倾向性评分匹配分析校正基线特征差异。

主要发现

  • 与PEC组相比,ECRF组新辅助放化疗使用更少(0% vs 29.5%,P<0.001)。
  • ECRF组病理III/IV期比例更低(31.6% vs 39.2%,P=0.036),但R1/2切缘更高(21.3% vs 10.9%,P<0.001)。
  • ECRF组住院死亡率更高(14.0% vs 7.1%,P=0.003),总体并发症更多(68.4% vs 56.4%,P=0.006)。
  • 匹配后,ECRF组5年总生存(28.8% vs 50.5%;HR=1.53,95%CI 1.15-2.04;P=0.003)和无事件生存(32.2% vs 42.5%;HR=1.56,95%CI 1.18-2.05;P=0.002)显著降低。
  • 肿瘤复发发生率或模式无显著差异;RIEC与NRIEC组匹配前后短期或长期结局均无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objectives of this study were to compare peri-operative and long-term outcomes from oesophageal cancer (EC) (i) that arose in a previously radiated field (ECRF) versus primary (PEC) and among ECRF patients and (ii) radiotherapy-induced (RIEC) versus non-radiotherapy-induced EC (NRIEC). METHODS: Data were collected from 30 European centres from 2000 to 2010. Two thousand four hundred eighty nine EC patients surgically treated were included in the PEC group and 136 in the ECRF group, NRIEC group (n = 61) and RIEC group (n = 75). Propensity score matching analyses were used to compensate for differences in baseline characteristics. RESULTS: Compared to the PEC group, the ECRF group was characterised by less use of neoadjuvant chemoradiotherapy (0% versus 29.5%; P < 0.001), less pathological stage III/IV (31.6% versus 39.2%, P = 0.036), greater incidence of R1/2 margins (21.3% versus 10.9%; P < 0.001), increased in-hospital mortality (14.0% versus 7.1%; P = 0.003) and overall morbidity (68.4% versus 56.4%, P = 0.006). After matching, 5-year overall (28.8% versus 50.5%; hazard ratio [HR] = 1.53, 95% confidence interval [CI]: 1.15-2.04; P = 0.003) and event-free (32.2% versus 42.5%; HR = 1.56, 95% CI: 1.18-2.05; P = 0.002) survivals were significantly reduced in the ECRF group. There were no significant differences in incidence or pattern of tumour recurrence. Comparing RIEC and NRIEC groups, there were no significant differences in short- or long-term outcomes before and after matching. CONCLUSIONS: ECRF is associated with poorer long-term survival related to a reduced utilisation of neoadjuvant chemoradiotherapy and an increased incidence of tumour margin involvement at surgery. Outcomes appear to be dictated by the limitations related to previous radiotherapy administration more than the radiotherapy-induced carcinogenesis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Markar SR, Gronnier C, Pasquer A, et al. Surgically treated oesophageal cancer developed in a radiated field: Impact on peri-operative and long-term outcomes. Eur J Cancer. 2017. PMID: 28236769. doi:10.1016/j.ejca.2016.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。